NCT00393120View on ClinicalTrials.gov

Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

HIV Infections

Interventions

DRUG

INCB009471

100mg SR (sustained release) orally once daily

DRUG

INCB009471

300mg SR (sustained release) orally once daily

DRUG

Placebo comparator

Orally once daily

Trial Locations (6)

20007

Washington D.C.

20037

Annandale

32803

Orlando

32960

Vero Beach

90069

Los Angeles

02130

Boston

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY